AstraZeneca CEO Pascal Soriot called the US drug pricing model 'unsustainable,' urging alignment with global rates. He supports linking prices to other nations for new drugs only. Backed by strong Q2 results and a $50 billion US expansion, retail sentiment on Stocktwits is 'bullish'. AZN shares are up 12.3% YTD.